尿毒清颗粒联合氯沙坦钾治疗早期糖尿病肾病的疗效及对氧化应激指标的影响

Curative Effect of Niaoduqing Granule (尿毒清颗粒) Combined with Losartan Potassium on Early Diabetic Nephropathy and Its Effect on Oxidative Stress Indicators

目的探讨尿毒清颗粒联合氯沙坦钾治疗早期糖尿病肾病的临床效果。方法以随机数字表法,将2018年1月—2019年7月收治的82例早期糖尿病肾病患者分为对照组和观察组,每组41例,均接受基础治疗,对照组加用氯沙坦钾,观察组在对照组基础上联合尿毒清颗粒,对两组治疗效果,治疗前、治疗3个月后肾功能指标、氧化应激指标变化及不良反应发生情况予以观察。结果治疗总有效率观察组为95.12%(39/41),与对照组80.49%(33/41)对比,差异有统计学意义(P<0.05);治疗前,两组血肌酐(Scr)、尿微量白蛋白(U-mAlb)、血尿素氮(BUN)对比,差异无统计学意义(P>0.05),治疗3个月后,与同期对照组对比,观察组上述指标水平明显较低(P<0.05);治疗前,两组超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、丙二醛(MDA)对比,差异无统计学意义(P>0.05),治疗3个月后,与同期对照组对比,观察组上述指标情况明显较好(P<0.05);不良反应发生率观察组为12.20%(5/41),与对照组14.63%(6/41)对比,差异无统计学意义(P>0.05)。结论尿毒清颗粒联合氯沙坦钾治疗早期糖尿病肾病,效果满意,可明显改善患者肾功能及氧化应激指标,且安全性高,值得推广。

Objective To explore the clinical effect of Niaoduqing granule (尿毒清颗粒) combined with losartan potassium in the treatment of early diabetic nephropathy. Methods Eighty-two patients with early diabetic nephropathy admitted to the hospital from Jan 2018 to Jul 2019 were divided into the control group and the observation group by the random number table method, 41 cases in each group. Both groups received basic treatment. The control group added losartan potassium, and the observation group was combined Niaoduqing granule on the basis of the control group. The treatment effect, the changes of renal function indicators and oxidative stress indicators before and after 3 months treatment and the adverse reactions of the two groups were observed. Results In the observation group, the total effective rate was 95.12% (39/41) and was significantly higher compared with that of the control group (80.49%,33/41) (P<0.05). Before treatment, there were no significant difference in serum creatinine (Scr), urine microalbumin (U-mAlb) or blood urea nitrogen (BUN) between the two groups (P>0.05). After 3 months of treatment, compared with those of the control group at the same period, the levels of above indicators in the observation group were significantly lower (P<0.05). Before treatment, there were no significant difference in superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) or malondialdehyde (MDA) between the two groups (P>0.05). After 3 months of treatment, compared with those of the control group at the same period, the above indicators in the observation group were significantly better (P<0.05). In the observation group, the incidence of adverse reactions was 12.20% (5/41) and had no significant difference compared with that of the control group (14.63%,6/41) (P>0.05). Conclusion Niaoduqing Granule combined with losartan potassium in the treatment of early diabetic nephropathy have satisfactory results and can significantly improve patients’ renal function and oxidative stress indicators. It has high safety, worthy of popularizing.